Overview
Background
Associate Professor Melissa Eastgate is the Executive Director of Cancer Care Services at the RBWH, and the stream lead Metro North HHS Cancer Care Services. Melissa is the immediate past Chair of the Medical Oncology Group of Australia. Melissa completed her medical degree at the University of Queensland and gained her FRACP in Medical Onoclogy in 2004. Since then she has worked at the RBWH as a medical oncologist, with her main clinical interests being melanoma and gastrointestinal cancers, in which areas she is an active researcher. Melissa established the Melanoma MDT at the RBWH. Melissa supervises physician trainees throughout their training and is the previous Chair of the RACP Advanced Training Committee for Medical Oncology. Melissa has a strong interest in enabling access to care for patients, having provided outreach services to Bundaberg for nine years, and leading the establishment of the Telechemotherapy service in Longreach and Barcaldine.
Availability
- Associate Professor Melissa Eastgate is:
- Not available for supervision
Research interests
-
Management of metastatic melanoma
-
Management of gastrointestinal cancers
-
Medical oncology training
Works
Search Professor Melissa Eastgate’s works on UQ eSpace
2025
Journal Article
Non-pharmacological supportive care interventions during immunotherapy for people with cancer: a systematic scoping review and future directions
Farley, Morgan J., Scanlon, Brighid, Crichton, Megan, Bigaran, Ashley, Barnes, Amy, Hart, Nicolas H., Yates, Patsy M., Eastgate, Melissa and Alexander, Kim (2025). Non-pharmacological supportive care interventions during immunotherapy for people with cancer: a systematic scoping review and future directions. Current Oncology Reports, 27 (12), 1507-1523. doi: 10.1007/s11912-025-01714-x
2025
Conference Publication
Australian patients with IDH<sub>1 </sub>mutatedcholangiocarcinoma treated with ivosidenib: initial resultsfrom the phase 3b ProvIDHe study
Price, Tim, Sim, Hao-Wen, Eastgate, Melissa, Mclachlan, Sue-Anne, Dean, Andrew, George, David, Weeratunge, Roshi, Zhang, Yoz and Oo, Maung Maung (2025). Australian patients with IDH1 mutatedcholangiocarcinoma treated with ivosidenib: initial resultsfrom the phase 3b ProvIDHe study. HOBOKEN: WILEY.
2025
Conference Publication
Retrospective cohort study of Treatment Patterns and Outcomes for Patients with locally advanced Rectal Cancer across Three Metropolitan Hospitals in Brisbane
Macilwraith, Philip, Turner, Cassie, Roberts, Kate, Bigby, Kieron, Kang, Sebastian, Wyld, David, Burge, Matthew and Eastgate, Melissa (2025). Retrospective cohort study of Treatment Patterns and Outcomes for Patients with locally advanced Rectal Cancer across Three Metropolitan Hospitals in Brisbane. HOBOKEN: WILEY.
2025
Conference Publication
Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) plus bevacizumab (B) plus transarterial chemoembolization (TACE) and placebos plus TACE: EMERALD-1 post hoc analysis
Roderburg, C., Sangro, B., Bouattour, M., Park, J. -W., Romero, M. Del Consuelo Diaz, Erinjeri, J. P., Alves, G., Gu, S., Manikhas, A., Kuroda, H., Suksombooncharoen, T., Vo, T. Hoi Trung, Ostwal, V. S., Eastgate, M., Vaccaro, G., Griffin, R., Ali, S., Balaji, K. and Chan, S. L. (2025). Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) plus bevacizumab (B) plus transarterial chemoembolization (TACE) and placebos plus TACE: EMERALD-1 post hoc analysis. BASEL: KARGER.
2025
Conference Publication
Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D)+bevacizumab (B)+transarterial chemoembolization (TACE) and placebos+TACE: EMERALD-1 post hoc analysis
Roderburg, C., Sangro, B., Bouattour, M., Park, J-W., del Consuelo Díaz Romero, M., Erinjeri, J. P., Alves, G., Gu, S., Manikhas, A., Kuroda, H., Suksombooncharoen, T., Hoi Trung Vo, T., Ostwal, V. S., Eastgate, M., Vaccaro, G., Griffin, R., Ali, S., Balaji, K. and Chan, S. L. (2025). Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D)+bevacizumab (B)+transarterial chemoembolization (TACE) and placebos+TACE: EMERALD-1 post hoc analysis. Annual conference of the German Society of Gastroenterology, and Digestive and Metabolic Diseases with Endoscopy Section (DGVS) Viszeralmedizin 2025, Leipzig, Germany, 15–20 September 2025. Stuttgart, Germany: Georg Thieme. doi: 10.1055/s-0045-1810980
2025
Journal Article
Depleting the action of EZH2 through PI3K-mTOR inhibition to overcome metastasis and immunotherapy resistance in triple-negative breast cancer
Melino, Michelle, Tu, Wen Juan., Bielefeldt-Ohmann, Helle, Proctor, Martina, Ahuja, Taniya, Vandermeide, John, Bain, Amanda L., Nallan, Gahyathiri, Goh, Sal Lee, Prasanna, Thiru, Dahlstrom, Jane E., Miranda, Mariska, Choudhary, Ramesh Kumar., Anandam, Aravind, Chaudhary, Sumit, Seal, Jonathan T., Sinha, Debottam, Zhang, Shaoqian, Nguyen, Tam Hong., Srihari, Sriganesh, Hartel, Gunter, Ives, Amy, Malik, Laeeq, Yip, Desmond, Nottage, Michelle, Eastgate, Melissa and Rao, Sudha (2025). Depleting the action of EZH2 through PI3K-mTOR inhibition to overcome metastasis and immunotherapy resistance in triple-negative breast cancer. Molecular Cancer Therapeutics, 24 (10), 1511-1526. doi: 10.1158/1535-7163.mct-24-0693
2025
Journal Article
Catheter-related thrombosis in adults with cancer: a secondary analysis of a prospective randomised controlled trial
Hapgood, Greg, Hill, Kate, Okano, Satomi, Abro, Emad, Looke, David, Kennedy, Glen, Pavilion, Gilbert, Van Kuilenburg, Rosita, Geary, Alanna, Joubert, Warren, Eastgate, Melissa, Jones, Mark and Mollee, Peter (2025). Catheter-related thrombosis in adults with cancer: a secondary analysis of a prospective randomised controlled trial. Journal of Thrombosis and Haemostasis, 23 (2), 627-634. doi: 10.1016/j.jtha.2024.11.002
2025
Conference Publication
Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + transarterial chemoembolization (TACE) and placebos + TACE: EMERALD-1 post hoc analysis
Sangro, Bruno, Bouattour, Mohamed, Park, Joong-Won, Diaz, Dr. Consuelo, Erinjeri, Joseph P., Alves, Gustavo Vasconcelos, Gu, Shan-Zhi, Manikhas, Aleksei, Kuroda, Hidekatsu, Suksombooncharoen, Thatthan, Vo, Truc Hoi Trung, Ostwal, Vikas S., Eastgate, Melissa A., Vaccaro, Gina M., Griffin, Rebecca, Ali, Sajid, Balaji, Kavitha and Chan, Stephen Lam (2025). Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + transarterial chemoembolization (TACE) and placebos + TACE: EMERALD-1 post hoc analysis. 2025 ASCO Gastrointestinal (GI) Cancers Symposium, San Francisco, CA United States, 23 - 25 January 2025. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.4_suppl.574
2025
Journal Article
Cost-effectiveness analysis of microwave ablation versus robot-assisted partial nephrectomy for patients with small renal masses in Australia
Xia, Qing, Senanayake, Sameera Jayan, Kularatna, Sanjeewa, Brain, David, McPhail, Steven M., Parsonage, Will, Eastgate, Melissa, Barnes, Annette, Brown, Nick and Carter, Hannah E. (2025). Cost-effectiveness analysis of microwave ablation versus robot-assisted partial nephrectomy for patients with small renal masses in Australia. Urologic Oncology, 43 (1), 62.e15-62.e26. doi: 10.1016/j.urolonc.2024.09.016
2024
Conference Publication
Baseline characteristics and molecular testing of Australian patients with IDH1 mutated cholangiocarcinoma: initial results from the phase IIIb ProvIDHe study
Sim, H-W., McLachlan, S-A., Dean, A., Price, T.J., Eastgate, M., Rimassa, L., Mercade, T. Macarulla, Malka, D., Gharbi, H., Robert, R., Sullivan, A. and Vogel, A. (2024). Baseline characteristics and molecular testing of Australian patients with IDH1 mutated cholangiocarcinoma: initial results from the phase IIIb ProvIDHe study. ESMO Asia Congress 2024, Singapore, 6 – 8 December 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2024.10.171
2024
Journal Article
Patient Reported Outcome Measures in cancer care: a hybrid effectiveness-Implementation trial to optimise Symptom control and health service Experience (PROMISE)–protocol for a randomised controlled trial of electronic self-reporting of symptoms versus usual care during and following treatment in patients with cancer
Webb, Penelope M, Brown, Amy, Brown, Bena, Collins, Louisa G, Crawford Williams, Fiona, Doupain, Kerrie, Eastgate, Melissa, Fennelly, Vicki, Girgis, Afaf, Hartel, Gunter, Ladwa, Rahul, Martin, Karen, Mason, Robert, McGuire, Peter, Miller, Elizabeth, O’Brien, Suzanne, Packer, Rebecca, Pinkham, Mark B, Sabesan, Sabe, Sanmugarajah, Jasotha, Slapp, Georgia, Tapsall, Doreen, White, Jeanie, Wishart, Laurelie R, Wyld, David and Chan, Raymond J (2024). Patient Reported Outcome Measures in cancer care: a hybrid effectiveness-Implementation trial to optimise Symptom control and health service Experience (PROMISE)–protocol for a randomised controlled trial of electronic self-reporting of symptoms versus usual care during and following treatment in patients with cancer. BMJ Open, 14 (11) e090836, 1-10. doi: 10.1136/bmjopen-2024-090836
2024
Conference Publication
"Signing up for the PRoCESS [Pancreatic cancer Relatives Counselling and Education Support Service] Trial was the most important thing I did as a carer"
Beesley, Vanessa L., Roset, Natalie, Turner, Jane, Yates, Patsy, Wyld, David, Eastgate, Melissa, Chan, Raymond, Collins, Louisa, Stewart, Michelle, Beebe, Hanna, Malt, Maryrose, Kelly, Caroline and Neale, Rachel (2024). "Signing up for the PRoCESS [Pancreatic cancer Relatives Counselling and Education Support Service] Trial was the most important thing I did as a carer". COSA's 51st Annual Scientific Meeting: Bridging gaps, building progress, breaking down disparities, Gold Coast, QLD, Australia, 13 - 15 November 2024. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.14116
2024
Journal Article
Bolusing IV administration sets with monoclonal antibodies reduces cost and chair time: a randomized controlled trial
Boyte, M. Francesca, Scanlon, Gradcert Brighid, Matthews, Robyn, Button, Elise, Jones, Lee, Hayes, Therese, Partridge, Grant, Smith, Michael, Kennedy, Glen Andrew, Eastgate, Melissa and Gavin, Nicole Clare (2024). Bolusing IV administration sets with monoclonal antibodies reduces cost and chair time: a randomized controlled trial. Clinical Journal of Oncology Nursing, 28 (5), E9-E15. doi: 10.1188/24.CJON.E9-E15
2024
Conference Publication
Routine, prospective DPYD genotyping guided dose-individualisation for patients receiving fluoropyrimidines: Implementation, prevalence and patient safety outcomes from a multi-institutional clinical trial
Nalder, Mark, Kulasegaran, Tivya, Lundie, Ben, Woods, Rick, Eastgate, Melissa A., Wyld, David and Burge, Matthew E. (2024). Routine, prospective DPYD genotyping guided dose-individualisation for patients receiving fluoropyrimidines: Implementation, prevalence and patient safety outcomes from a multi-institutional clinical trial. 2024 ASCO Annual Meeting, Chicago, IL, United States, 31 May–4 June 2024. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2024.42.16_suppl.12121
2024
Journal Article
Exploring the administration of intravenous antibiotics and fluids via portable intravenous pump versus intravenous pump and pole to improve mobility in patients diagnosed with cancer (The ACTIVE Trial): A randomized controlled trial protocol
Matthews, Robyn, Russell, Emily, Wessling, Claire, Sandler, Carolina, Eastgate, Melissa, Hajkowicz, Krispin, Pavey, Toby, Clark, Bronwyn K., Scanlon, Brighid and Gavan, Nicole C. (2024). Exploring the administration of intravenous antibiotics and fluids via portable intravenous pump versus intravenous pump and pole to improve mobility in patients diagnosed with cancer (The ACTIVE Trial): A randomized controlled trial protocol. Vascular Access Journal of the Canadian Vascular Access Association, 18 (2), 44-58. doi: 10.5737/va.v18.i2.44
2023
Journal Article
Does bolusing intravenous administration sets with monoclonal antibodies reduce chair time in the oncology outpatient setting? A protocol for a randomized controlled trial
Gavin, Nicole, Boyte, Francesca, Matthews, Robyn, Button, Elise, Jones, Lee, Hayes, Therese, Partridge, Grant, Smith, Michael, Kennedy, Glen and Eastgate, Melissa (2023). Does bolusing intravenous administration sets with monoclonal antibodies reduce chair time in the oncology outpatient setting? A protocol for a randomized controlled trial. Vascular Access, 17 (3), 8-25.
2023
Conference Publication
CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma
Lau, Peter Kar Han, Harris, Samuel John, Eastgate, Melissa A., Kee, Damien, Mant, Andrew, Nott, Louise M., Gedye, Craig, Inderjeeth, Andrisha Jade, Underhill, Craig, Weppler, Alison Margaret, Wallace, Roslyn, Lee, Belinda, Au-Yeung, George, Williams, Narelle, Ariza Ospino, Daniel, Gonzales, Louise, Shackleton, Mark J., Lo, Serigne N., McArthur, Grant A. and Sandhu, Shahneen (2023). CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma. 2023 ASCO Annual Meeting, Chicago, IL United States, 2-6 June 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.16_suppl.9525
2023
Conference Publication
Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic esophageal and gastroesophageal carcinoma with dysphagia: A single arm phase 2 clinical trial, PALEO
Day, Fiona, Sridharan, Swetha, Michael, Michael, Christophersen, Louise, Moore, Melissa M., Eastgate, Melissa A., Thompson, Stephen, MWEEMPWA, ANGELA, Oldmeadow, Christopher, Fraser, Allison and Martin, Jarad (2023). Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic esophageal and gastroesophageal carcinoma with dysphagia: A single arm phase 2 clinical trial, PALEO. 2023 ASCO Annual Meeting, Chicago, IL United States, 2-6 June 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.16_suppl.tps4172
2023
Journal Article
Investigating the dietary knowledge, attitudes, and beliefs of Australian patients with cancer
Lee, Shu Fen, Brown, Teresa, Wyld, David, Edwards, Anna and Eastgate, Melissa (2023). Investigating the dietary knowledge, attitudes, and beliefs of Australian patients with cancer. Journal of Human Nutrition and Dietetics, 36 (3), 612-621. doi: 10.1111/jhn.13091
2022
Conference Publication
A multicenter, randomized, double-blind phase III study of HBI-8000 combined with nivolumab versus placebo with nivolumab in patients with unresectable or metastatic melanoma not previously treated with PD-1 or PD-L1 inhibitors
Khushalani, N.I., Shue, H., Gedye, C., Mazumder, A., Sharma, S., Eastgate, M., Majem Tarruella, M., Antonanzas Basa, M., Montaudie, H., Marais-Nieman, R., de la Cruz Merino, L., Clements, A., Mortier, L., Jameson, M., Shojaei, F., Ning, J., Aiyer, L., Gillings, M., Kabbinavar, F. and Ascierto, P. (2022). A multicenter, randomized, double-blind phase III study of HBI-8000 combined with nivolumab versus placebo with nivolumab in patients with unresectable or metastatic melanoma not previously treated with PD-1 or PD-L1 inhibitors. ESMO Asia Congress 2022, Singapore, 2-4 December 2022. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2022.10.052
Media
Enquiries
For media enquiries about Associate Professor Melissa Eastgate's areas of expertise, story ideas and help finding experts, contact our Media team: